A defining feature of the 2026 healthcare system is the Fourth Temporary Extension of telemedicine flexibilities. The DEA and the Department of Health and Human Services (HHS) have officially extended the ability for registered practitioners to prescribe Schedule II-V controlled substances via telehealth through December 31, 2026. This extension is vital for maintaining continuity of care for patients who cannot easily visit a clinic in person.
